×
About 4,693 results

ALLMedicine™ Thrombotic Thrombocytopenic Purpura Center

Research & Reviews  2,255 results

Annual Incidence and Severity of Acute Episodes in Hereditary Thrombotic Thrombocytopen...
https://doi.org/10.1182/blood.2020009801
Blood Tarasco E, Bütikofer L et. al.

Mar 2nd, 2021 - Hereditary thrombotic thrombocytopenic purpura (hTTP) is a rare thrombotic microangiopathy characterized by severe congenital ADAMTS13 deficiency and recurring acute episodes causing morbidity and premature death. Information on the annual inciden...

Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay...
https://doi.org/10.3324/haematol.2020.278244
Haematologica Hrdinová J, D'Angelo S et. al.

Mar 1st, 2021 - Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers.|2021|Hrdinová J,D'Angelo S,Graça NAG,Ercig B,Vanhoorelbeke K,|

Unfolding the pathophysiology of congenital thrombotic thrombocytopenic purpura in preg...
https://doi.org/10.1016/j.ajog.2021.02.018
American Journal of Obstetrics and Gynecology; Miodownik S, Pikovsky O et. al.

Feb 23rd, 2021 - Thrombotic Thrombocytopenic Purpura (TTP), a rare, potentially life-threatening thrombotic microangiopathy, manifests as both congenital (cTTP) and acquired forms. It is caused by the absence of or severe depletion in a disintegrin and metalloprot...

Immune-mediated thrombotic thrombocytopenic purpura in childhood treated by caplacizuma...
https://doi.org/10.1007/s40620-021-00992-5 10.1182/blood-2016-10-709857 10.1080/17474086.2019.1611423 10.1002/rth2.12160 10.1056/NEJMoa1505533 10.1056/NEJMoa1806311 10.1002/pbc.27737 10.1002/pbc.28534 10.1007/s00467-019-04281-z 10.1016/j.lpm.2019.08.024 10.1016/S2352-3026(16)30125-9 10.1111/ejh.13107 10.1182/blood.2020008021 10.1182/blood.2020007599
Journal of Nephrology; Boudali J, Hallak B et. al.

Feb 22nd, 2021 - Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare disease in adults and exceptional in childhood. Caplacizumab has proven its effectiveness in the treatment of iTTP in adulthood in association with standard of care. Unfortunatel...

see more →

Guidelines  11 results

CABLIVI (caplacizumab-yhdp) Prescribing Information
http://products.sanofi.us/cablivi/cablivi.pdf

Feb 5th, 2019 - CABLIVI is a von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

FDA approves Cablivi, first treatment for acquired thrombotic thrombocytopenic purpura
https://www.healio.com/hematology-oncology/hematology/news/online/%7Be91d83f6-8859-412b-970c-198151f0b208%7D/fda-approves-cablivi-first-treatment-for-acquired-thrombotic-thrombocytopenic-purpura
Pazdur,R.

Feb 5th, 2019 - The FDA today approved caplacizumab-yhdp injection as the first therapy specifically indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura, a rare and life-threatening blood clotting disorder.

FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
http://hugin.info/152918/R/2233733/878824.pdf

Feb 5th, 2019 - The U.S. Food and Drug Administration (FDA) has approved Cablivi® (caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Cablivi is the firs...

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
https://www.nejm.org/doi/10.1056/NEJMoa1806311
Scully,M.,et al

Jan 23rd, 2019 - In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis, which re...

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
https://www.jwatch.org/na48305/2019/01/17/caplacizumab-acquired-thrombotic-thrombocytopenic-purpura
Green,David

Jan 16th, 2019 - Patients with acquired thrombotic thrombocytopenic purpura (TTP) have von Willebrand factor (VWF)–mediated platelet aggregates that ...HERCULES Trial

see more →

Drugs  13 results see all →

Clinicaltrials.gov  2,307 results

Annual Incidence and Severity of Acute Episodes in Hereditary Thrombotic Thrombocytopen...
https://doi.org/10.1182/blood.2020009801
Blood Tarasco E, Bütikofer L et. al.

Mar 2nd, 2021 - Hereditary thrombotic thrombocytopenic purpura (hTTP) is a rare thrombotic microangiopathy characterized by severe congenital ADAMTS13 deficiency and recurring acute episodes causing morbidity and premature death. Information on the annual inciden...

Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay...
https://doi.org/10.3324/haematol.2020.278244
Haematologica Hrdinová J, D'Angelo S et. al.

Mar 1st, 2021 - Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers.|2021|Hrdinová J,D'Angelo S,Graça NAG,Ercig B,Vanhoorelbeke K,|

Unfolding the pathophysiology of congenital thrombotic thrombocytopenic purpura in preg...
https://doi.org/10.1016/j.ajog.2021.02.018
American Journal of Obstetrics and Gynecology; Miodownik S, Pikovsky O et. al.

Feb 23rd, 2021 - Thrombotic Thrombocytopenic Purpura (TTP), a rare, potentially life-threatening thrombotic microangiopathy, manifests as both congenital (cTTP) and acquired forms. It is caused by the absence of or severe depletion in a disintegrin and metalloprot...

Immune-mediated thrombotic thrombocytopenic purpura in childhood treated by caplacizuma...
https://doi.org/10.1007/s40620-021-00992-5 10.1182/blood-2016-10-709857 10.1080/17474086.2019.1611423 10.1002/rth2.12160 10.1056/NEJMoa1505533 10.1056/NEJMoa1806311 10.1002/pbc.27737 10.1002/pbc.28534 10.1007/s00467-019-04281-z 10.1016/j.lpm.2019.08.024 10.1016/S2352-3026(16)30125-9 10.1111/ejh.13107 10.1182/blood.2020008021 10.1182/blood.2020007599
Journal of Nephrology; Boudali J, Hallak B et. al.

Feb 22nd, 2021 - Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare disease in adults and exceptional in childhood. Caplacizumab has proven its effectiveness in the treatment of iTTP in adulthood in association with standard of care. Unfortunatel...

see more →

News  107 results

NICE Recommends Innovative Treatment for Severe Blood Disorder for NHS Use
https://www.medscape.com/viewarticle/941022

Nov 15th, 2020 - A brand-new treatment – one of the first for 25 years – for acute acquired thrombotic thrombocytopenic purpura (aTTP) has been recommended by the National Institute for Health and Care Excellence (NICE) for routine use in the NHS. Caplacizumab (Ca...

2019 at a glance: Hem-onc U.S. drug approvals
https://www.mdedge.com/jcomjournal/article/211340/mixed-topics/2019-glance-hem-onc-us-drug-approvals/page/0/1?channel=325

Oct 31st, 2019 - Caplacizumab-yhdp (Cablivi) Class: Monoclonal antibody fragment directed against von Willebrand factor. Disease: Thrombotic thrombocytopenic purpura.

In older patients with immune-mediated TTP, atypical features may delay diagnosis
https://www.mdedge.com/hematology-oncology/article/209753/bleeding-disorders/older-patients-immune-mediated-ttp-atypical?channel=39313
Andrew D. Bowser

Oct 9th, 2019 - Older patients with immune thrombotic thrombocytopenic purpura (iTTP) more often have an atypical neurological presentation, which could result in a delayed diagnosis, according to authors of a recent retrospective analysis. “Practitioners should.

TTP death linked to elevated troponin and neurological signs
https://www.mdedge.com/internalmedicine/article/199586/bleeding-disorders/ttp-death-linked-elevated-troponin-and?channel=285
Will Pass

Apr 25th, 2019 - GLASGOW – Neurological abnormalities and elevated troponin predict mortality in patients with thrombotic thrombocytopenic purpura (TTP), according to retrospective analysis of 475 patients from the United Kingdom TTP registry. Will Pass/MDedge New.

Novel Assay Reveals Optimal Treatment in Rare Blood Disorder
https://www.staging.medscape.com/viewarticle/911288

Apr 3rd, 2019 - GLASGOW — Combining prophylactic infusions and anti-platelet therapy normalises thrombus formation in patients with congenital thrombotic thrombocytopenic purpura (TTP) under shear flow conditions, reveals a novel assay developed by UK researchers...

see more →